The acridone derivative MBLI-87 sensitizes breast cancer resistance protein-expressing xenografts to irinotecan.

[1]  W. Löscher,et al.  Blood-brain barrier active efflux transporters: ATP-binding cassette gene family , 2011, NeuroRX.

[2]  F. Blackhall,et al.  Gefitinib for the treatment of non-small-cell lung cancer , 2010, Expert opinion on pharmacotherapy.

[3]  J. Putaux,et al.  Colloidal systems made of biotransesterified α, β and γ cyclodextrins grafted with C10 alkyl chains , 2009 .

[4]  Joseph W. Polli,et al.  An Unexpected Synergist Role of P-Glycoprotein and Breast Cancer Resistance Protein on the Central Nervous System Penetration of the Tyrosine Kinase Inhibitor Lapatinib (N-{3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine; GW572016) , 2009, Drug Metabolism and Disposition.

[5]  P. Carrupt,et al.  QSAR analysis and molecular modeling of ABCG2-specific inhibitors. , 2009, Advanced drug delivery reviews.

[6]  J. Ware,et al.  Curcumin Inhibits the Activity of ABCG2/BCRP1, a Multidrug Resistance-Linked ABC Drug Transporter in Mice , 2009, Pharmaceutical Research.

[7]  T. Fojo,et al.  Bevacizumab reduces the growth rate constants of renal carcinomas: a novel algorithm suggests early discontinuation of bevacizumab resulted in a lack of survival advantage. , 2008, The oncologist.

[8]  G. Jansen,et al.  Drug transporters: recent advances concerning BCRP and tyrosine kinase inhibitors , 2008 .

[9]  J. Putaux,et al.  Miscellaneous nanoaggregates made of beta-CD esters synthesised by an enzymatic pathway. , 2007, International journal of pharmaceutics.

[10]  M. Pomper,et al.  ABCG2/BCRP expression modulates D-Luciferin based bioluminescence imaging. , 2007, Cancer research.

[11]  A. di Pietro,et al.  Acridone derivatives: design, synthesis, and inhibition of breast cancer resistance protein ABCG2. , 2007, Bioorganic & medicinal chemistry.

[12]  S. Bates,et al.  Toward individualized treatment: prediction of anticancer drug disposition and toxicity with pharmacogenetics , 2007, Anti-cancer drugs.

[13]  P. Houghton,et al.  Gefitinib modulates the function of multiple ATP-binding cassette transporters in vivo. , 2006, Cancer research.

[14]  Alex Sparreboom,et al.  Pharmacogenetics of irinotecan metabolism and transport: an update. , 2006, Toxicology in vitro : an international journal published in association with BIBRA.

[15]  Y. Wong,et al.  Nanoparticles of β-Cyclodextrin Esters Obtained by Self-Assembling of Biotransesterified β-Cyclodextrins , 2006 .

[16]  Y. Wong,et al.  Nanoparticles of beta-cyclodextrin esters obtained by self-assembling of biotransesterified beta-cyclodextrins. , 2006, Biomacromolecules.

[17]  Francisco Gamarro,et al.  Flavonoid structure-activity studies identify 6-prenylchrysin and tectochrysin as potent and specific inhibitors of breast cancer resistance protein ABCG2. , 2005, Cancer research.

[18]  G. Kéri,et al.  Multidrug transporter ABCG2 prevents tumor cell death induced by the epidermal growth factor receptor inhibitor Iressa (ZD1839, Gefitinib). , 2005, Cancer research.

[19]  Peter J Houghton,et al.  Gefitinib Enhances the Antitumor Activity and Oral Bioavailability of Irinotecan in Mice , 2004, Cancer Research.

[20]  Y. Sugimoto,et al.  Gefitinib reverses breast cancer resistance protein-mediated drug resistance. , 2004, Molecular cancer therapeutics.

[21]  S. Bates,et al.  Mutations at amino-acid 482 in the ABCG2 gene affect substrate and antagonist specificity , 2003, British Journal of Cancer.

[22]  Y. Sugiyama,et al.  Active efflux of CPT-11 and its metabolites in human KB-derived cell lines. , 1999, The Journal of pharmacology and experimental therapeutics.